COMMUNIQUÉS West-GlobeNewswire

Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)

15/11/2024 - 17:00

Phase 2 study results to be presented at The Liver Meeting ® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants with undetectable [...]

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15/11/2024 - 17:00

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. [...]

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit

15/11/2024 - 17:00

Ipsen met en avant 3 nouvelles présentations ainsi que 8 abstracts dans le cadre de son portefeuille de maladies cholestatiques rares du foie au congrès 2024 de l’AASLD. L’utilisation d’Iqirvo a été approuvée aux États- [...]

Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®

15/11/2024 - 17:00

Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals BOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE [...]

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15/11/2024 - 17:00

-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage [...]

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

15/11/2024 - 17:00

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

15/11/2024 - 17:00

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of [...]

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

15/11/2024 - 16:12

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations 1 In the [...]

The Testosterone Project Launches on National Testosterone Awareness Day, November 17

15/11/2024 - 15:49

New Nonprofit Founded by Leading Testosterone Experts Seeks to Provide Equal Access to Care for Both Men and Women RALEIGH, N.C., Nov. 15, 2024 (GLOBE NEWSWIRE) -- The Testosterone Project , a new nonprofit founded by [...]

Arthritis VIP Founder Dr. Mark Hawass Scoops Prestigious UK ‘Impact Award’

15/11/2024 - 15:40

LONDON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Dr. Mark Hawass, the trailblazing founder of Arthritis VIP , has been honoured with an esteemed ‘Impact Award’ from Big Business Events, the fastest-growing business coaching [...]

Organogenesis Commends Final LCDs

15/11/2024 - 15:25

Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading [...]

LogicMark, Inc. Announces Reverse Stock Splits

15/11/2024 - 15:15

LOUISVILLE, Ky., Nov. 15, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK) (the “Company”), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing [...]

Trinity Biotech Announces Q3 2024 Financial Results

15/11/2024 - 15:00

Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve [...]

Outset Medical to Present at the 2024 Stifel Healthcare Conference

15/11/2024 - 15:00

SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]

Scientific Industries Reports Third Quarter 2024 Financial Results

15/11/2024 - 15:00

BIOPROCESSING OPERATIONS RECORDS 3 CONSECUTIVE QUARTERS OF REVENUE GROWTH OPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSSES BY 46% AND 34% TWO MAJOR NEW PRODUCTS TO LAUNCH IN Q1 2025 Investor Call to be held [...]

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

15/11/2024 - 15:00

PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

15/11/2024 - 15:00

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]

Samsung Bioepis Receives Positive CHMP Opinion for Denosumab Biosimilars, OBODENCE™ and XBRYK™

15/11/2024 - 14:30

OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectively INCHEON, South Korea, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., [...]

Sienna Announces November Dividend

15/11/2024 - 14:30

MARKHAM, Ontario, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]